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Abstract
We have previously demonstrated that assessment of antisaccades (AS) provides not only measures of motor function in
multiple sclerosis (MS), but measures of cognitive control processes in particular, attention and working memory. This study
sought to demonstrate the potential for AS measures to sensitively reflect change in functional status in MS. Twenty-four
patients with relapsing-remitting MS and 12 age-matched controls were evaluated longitudinally using an AS saccade task.
Compared to control subjects, a number of saccade parameters changed significantly over a two year period for MS
patients. These included saccade error rates, latencies, and accuracy measures. Further, for MS patients, correlations were
retained between OM measures and scores on the PASAT, which is considered the reference task for the cognitive
evaluation of MS patients. Notably, EDSS scores for these patients did not change significantly over this period. These results
demonstrate that OM measures may reflect disease evolution in MS, in the absence of clinically evident changes as
measured using conventional techniques. With replication, these markers could ultimately be developed into a cost-
effective, non-invasive, and well tolerated assessment tool to assist in confirming progression early in the disease process,
and in measuring and predicting response to therapy.
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Introduction
Multiple sclerosis is a multifocal inflammatory demyelinating
disease, with a pathophysiological process that involves the
interplay of damage and repair mechanisms. During acute relapse,
inflammatory demyelination causes conduction block and slowing
of action potentials leading to physical symptoms. Once resolved,
processes such as remyelination, sodium channel reorganisation
and cortical plasticity contribute to recovery of function. However,
through accumulation of residual damage and degenerative
changes the disease course eventually transforms into uninterrupt-
ed progression. These processes vary considerably both within and
between patients, resulting in a highly unpredictable clinical
course.
Unfortunately, current clinical assessments provide a crude
measure of functional change in MS patients. The most commonly
used clinical tool, the Kurtzke Expanded Disability Scale (EDSS)
[1], is widely criticised as a blunt instrument, with scores largely
biased towards pyramidal function. Not only is the EDSS
relatively insensitive to change, it provides little information about
other important functions, particularly cognitive function and the
integration of sensory and cognitive processes. Cognitive changes
are present in up to 70% of MS patients [2,3], even where
diagnosis is only probable [4]. Further, the correlation between the
clinical manifestations of the disease and the burden of lesions
observed on conventional magnetic resonance imaging (MRI)
scans remains weak. Not only are white matter (WM) lesions often
clinically silent, but conventional techniques offer a limited
capacity to characterize and quantify the heterogeneous features
of MS pathology, occult changes in normal appearing white
matter as well as damage to grey matter. Significantly, brain
volumes reduce regardless of continuing inflammatory activity,
demonstrating an important neurodegenerative component.
While more modern quantitative MRI techniques have the
potential to overcome some of the limitations of conventional
measures, their cost, availability, complexity and lack of validation
limit their use in routine clinical practice [5]. It is therefore crucial
from a clinical perspective, that we concurrently develop user-
friendly, cost-effective surrogate markers of disease activity that
provide sensitive assessment of functional change. This is
particularly important as new therapies evolve.
We have previously demonstrated that assessment of ocular
motor (OM) function provides not only a measure of lower level
motor control processes, but of impaired cognitive control
processes in MS [6,7,8]. In a cross-sectional study of 25 patients,
attentional and working memory deficits were reflected in
difficulty inhibiting a response to a non-target stimulus, protracted
and more variable movement onsets, and poor spatial accuracy.
Importantly, these deficits correlated significantly with scores on
neuropsychological tests commonly used in MS, including the
Paced Auditory Serial Addition Task (PASAT), considered the
reference task for the cognitive evaluation of MS patients [9].
This study sought to demonstrate the potential for OM
measures to sensitively reflect change in functional status in MS,
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relapsing-remitting MS (RRMS) and age-matched control were
retested on the AS task approximately two years following initial
testing (M=23.83 mths, range 23–29 mths). We propose that
these measures may ultimately provide para-clinical or surrogate
markers of (dys)function which can be used to assess relapse,
progression, recovery, and the consequences of therapeutic
intervention in MS.
Materials and Methods
Ethics statement
Ethics approval was granted by the Melbourne Health Human
Research Ethics Committee and all participants gave written
informed consent prior to inclusion in the study, in accordance
with the Helsinki declaration.
Participants
Twenty four patients meeting the McDonald criteria for RRMS
participated in this study. Mean age at follow-up was 41 years
(range 26–56 years), mean disease duration was 87 mths (range
28–200 mths), and scores using the Expanded Disability Status
Scale (EDSS) ranged from 0–5 (median score of 1). Ten patients
had a clinical score of 0 on the EDSS. Eleven patients experienced
new episodes in the interim between testing sessions, although
none were retested within 3 months of a relapse. Twelve age-
matched neurologically healthy individuals [mean age of 43 years
(range 29–64 years)] served as a control group. Exclusion criteria
for control subjects were a history of head injury, central
neurological disorder or psychiatric illness, drug abuse, or regular
intake of psychoactive drugs. All MS patients continued with their
normal medication regime.
Equipment
Horizontal displacement of the eye was recorded using an IRIS
infrared eye tracker (Skalar Medical, BV, Delft, The Netherlands),
with output sampled at 1 kHz. Screen based stimuli were
displayed on a 21 inch monitor (Mitsubishi Electric Corporation,
Tokyo, Japan), and generated using E-Prime software (Psychology
Software Tools, Inc, PA, USA). Participants were seated 840 mm
directly in front of the monitor with their heads stabilized using a
custom-made bite bar. Test stimuli were presented on a black
background and comprised green targets (cross; 30 mm630 mm)
presented centrally, 5u or 10u from centre in either hemifield, and
a white centrally-positioned re-fixation stimulus (square ring,
10 mm610 mm). Output from the eye tracker was displayed
alongside a control signal generated by E-Prime, which indicated
stimulus change. A photodiode was placed directly over a non-
visible portion of the screen to concurrently record stimulus
change in real-time.
Antisaccade task
Participants were instructed to fixate a centrally-positioned
target. Following a period of either 1250 or 1600 msec, this target
was extinguished coincident with the appearance of a peripheral
target. Participants were instructed not to look at the peripheral
target but to make a saccade in the opposite direction as quickly
and accurately as possible, ending an equal distance from the
centre of the screen. The peripheral target was extinguished after
1500 msec and a re-fixation stimulus, presented for 150 msec,
redirected gaze back to centre prior to the onset of the next trial.
The task included 48 trials (24 left, 24 right, balanced for 5u and
10u steps).
Neuropsychological tests
Attention, working memory, and speed of information process-
ing were assessed using the Paced Auditory Serial Addition Task
(PASAT). The PASAT is considered the reference task for the
cognitive evaluation of MS patients, and involves the presentation
of single digits presented every 3 (or 2) seconds with the participant
adding each new digit to the one immediately prior to it.
Depressive symptoms were evaluated using the Beck Depression
inventory (Beck and Steer, 1991). Standardised instructions were
followed
Statistical analyses
Key measures were proportion of errors (to non-target stimuli),
saccade latency, and mean absolute position error [(EPfinal2SP)/
SP]6100, where Epfinal is the final eye position and SP is the
stimulus position. Absolute change over time was calculated for all
variables and means for MS patients and control subjects were
compared using standard parametric (t-test or Welch test where a
violation of the assumption of equal variance was evident) and
non-parametric tests where appropriate (Mann-Whitney U).
Neuropsychological tests scores were correlated against OM
measures for MS patients using Pearson’s r.
Results
Means
An important finding here was that for control subjects, no
significant change was found over two years for any experimental
variable. However, compared to control subjects, changes in AS
saccade parameters were significantly greater for MS patients (see
Table 1): these included AS error rate, U=66.5, z=22.33,
p,0.05 (see Figure 1), and AS latency, U=69, z=22.12, p,0.05,
with a near significant difference in AS position error, t(34)=1.89,
p=0.06 (see Figure 2). Of note, EDSS scores for these patients did
not change significantly over the two year period, and did not
correlate with any experimental variable (mean EDSS=1.46 at
entry, and 1.14 at two years, p=0.282)
Correlations
For MS patients, significant correlations were revealed between
PASAT scores (% correct) and AS error rate (r=2.54, p,0.01),
and AS position error (r=2.54, p,0.01), see Figures 3 and 4.
Discussion
In a two-year follow-up study of RRMS patients we found that,
compared to control subjects, a range of saccade parameters
altered significantly, in particular those proposed to reflect
attentional and working memory processes. Importantly, these
alterations were evident in the absence of any clinically evident
change in functional status, and associations with neuropsycho-
logical assessments were maintained over time. In particular, error
Table 1. Mean absolute differences in saccade parameters
over two years.
MS Controls
AS Errors (%) 12.94 6.33
AS Latency (msec) 34.40 17.90
AS Position error (%) 8.92 5.56
doi:10.1371/journal.pone.0030475.t001
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PASAT, a complex test of executive function, working memory,
information processing speed and divided attention, commonly
used in MS.
Although saccadic dysmetria, internuclear ophthalmoplegia,
and fixation instability are clinically recognised features of MS
[10], each depend largely on the integrity of defined areas of the
brainstem. However, the control of more volitional saccadic eye
movements, like those investigated here, involves a reciprocally
connected, and widely distributed cortical/sub-cortical network,
which integrates complex afferent and efferent information to
generate appropriate, context-specific responses. Like cognitive
function more generally, diffuse disturbance of long-range links, as
would be expected in MS, disrupts activity inside this large,
distributed network [11,12,13]. Subsequently, change, whether a
function of further damage or repair, are reflected in altered
performance.
As the clinical and radiological course of MS is highly variable,
this group of patients necessarily comprised individuals whose
functional status had stabilised, improved or deteriorated, hence
our reporting absolute change. However, we would anticipate that
assessment over a significantly longer period would reflect
accumulated deficit, thus functional decline using our select OM
measures. Interestingly, a 2-year follow-up study by Derwenskus
et al (2005) [10] using observational analyses of OM function,
revealed an increase in deficits not represented by Kurtzke (EDSS)
scores of brainstem or cerebellar function (e.g. number of
inaccurate gaze shifts, number of saccadic intrusions). Like our
group, many of these patients had an otherwise full range of
movement, and therefore deficits would not have been detected
using conventional measures.
As for any useful biomarker in MS, we have demonstrated that
OM measures are accurate, reproducible and highly sensitive to
change in disease status. Notably, deficits were found irrespective
of initial clinical status, even in patients who scored ‘0’ on the
EDSS. We have also demonstrated correlation with other,
Figure 2. Change in AS position error over two years.
doi:10.1371/journal.pone.0030475.g002
Figure 3. Correlation between AS errors and PASAT scores in
MS patients at two years.
doi:10.1371/journal.pone.0030475.g003
Figure 1. Change in proportion of AS errors over two years.
doi:10.1371/journal.pone.0030475.g001
Figure 4. Correlation between AS position error and PASAT
scores in MS patients at two years.
doi:10.1371/journal.pone.0030475.g004
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is cost-effective, non-invasive, and well tolerated. With replication
in larger, well-defined cohorts, these markers could be developed
to complement other diagnostic and exploratory studies, affording
a degree of quantification not found in methods currently used in
MS.
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